衰减系数联合B型超声早期识别脂肪性肝病的前瞻性评估
前瞻性纳入128例转诊行肝脏弹性成像的患者,评估超声定量衰减系数(ATT)联合B型超声检测脂肪变性的效用。ATT诊断脂肪变的AUROC为0.894,优于肝肾指数(0.796),与CAP(0.896)相近;最佳阈值≥0.66 dB/cm/MHz时敏感度82.7%、特异度77.3%。在B型超声未见脂肪变的患者中,ATT≥0.66额外识别15例,其代谢综合征患病率显著更高(53.3% vs 19.5%,p=0.02)。
要点
- ATT诊断脂肪变性能优于B型超声和HRI,与CAP接近,可作为B型超声的补充。
- ATT阈值≥0.66 dB/cm/MHz时敏感度82.7%、特异度77.3%,可用于早期筛查。
- B型超声阴性但ATT≥0.66者代谢综合征比例更高,提示额外风险分层价值。
关键影像表现/征象
- B型超声将脂肪变分为正常(44.5%)、轻度(10.2%)、中度(21.1%)和重度(24.2%)。
- ATT与CAP强相关,提示ATT可作为CAP的替代定量指标。
- B型超声未见脂肪变的患者中,ATT≥0.66额外识别15例,其代谢综合征患病率显著高于ATT<0.66者(53.3% vs 19.5%,p=0.02)。
诊断标准与关键数值
- ATT检测脂肪变的AUROC为0.894,HRI为0.796,CAP为0.896。
- ATT最佳阈值≥0.66 dB/cm/MHz,检测脂肪变的敏感度82.7%、特异度77.3%。
临床应用与阅片要点
- 在B型超声未检出脂肪变但存在代谢风险的患者中,可加做ATT以发现早期脂肪变。
- ATT≥0.66 dB/cm/MHz可作为提示代谢综合征高风险的参考阈值,辅助报告分层。
局限性
- 单中心前瞻性研究,样本量128例,结论需多中心验证。
- 研究对象为转诊行肝脏弹性成像的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is highly prevalent, but B-mode ultrasound has limited sensitivity for detecting mild steatosis. We evaluated the utility of attenuation coefficient (ATT), an ultrasound-based quantitative tool, combined with B-mode ultrasound for early steatosis detection. In this prospective study, we enrolled 128 patients referred for liver elastography and collected data on B-mode ultrasound, hepato-renal index (HRI), ATT, and controlled attenuation parameter (CAP). The mean age was 56.8 ± 12.8 years, and 61.7% were male. B-mode ultrasound classified steatosis as normal (44.5%), mild (10.2%), moderate (21.1%), or severe (24.2%). The AUROC for detecting steatosis was 0.796 for HRI, 0.894 for ATT, and 0.896 for CAP. ATT correlated strongly with CAP, and the optimal ATT threshold (≥ 0.66 dB/cm/MHz) yielded a sensitivity of 82.7% and specificity of 77.3% for steatosis detection. Among patients without steatosis on B-mode ultrasound, an ATT ≥ 0.66 identified 15 additional individuals, with a significantly higher prevalence of metabolic syndrome (53.3% vs. 19.5%, p = 0.02). This represented a 21% relative increase in detecting patients at risk of MASLD. ATT enhances the diagnostic performance of B-mode ultrasound for hepatic steatosis and enables earlier identification of patients at risk for MASLD. Its integration into routine imaging represents a scalable, accessible, and non-invasive strategy for metabolic risk stratification.
引用
- Gonçalves JC, Souto M, Ferreira AI, et al. Early identification of patients with steatotic liver disease: Prospective evaluation of attenuation coefficient as an add-on to B-mode ultrasound. Eur J Radiol. 2026. PMID: 42361708. doi:10.1016/j.ejrad.2026.113035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。